Long-term safety of tezepelumab in Japanese Subjects with Inadequately Controlled Severe Asthma

Trial Identifier: D5180C00019
Sponsor: AstraZeneca
Collaborator:
Amgen
NCTID:: NCT04048343
Start Date: June 2019
Primary Completion Date: March 2021
Study Completion Date: March 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Japanese Translation

Trial Locations

Country Location
Japan Chuo-ku, Japan, 104-0031
Japan Chuo-ku, Japan, 103-0022
Japan Sagamihara-shi, Japan, 228-0815
Japan Shinagawa-ku, Japan, 140-8522
Japan Shinjuku-ku, Japan, 169-0073